JP2023538326A - プロテアソームエンハンサ及びその使用 - Google Patents

プロテアソームエンハンサ及びその使用 Download PDF

Info

Publication number
JP2023538326A
JP2023538326A JP2023509839A JP2023509839A JP2023538326A JP 2023538326 A JP2023538326 A JP 2023538326A JP 2023509839 A JP2023509839 A JP 2023509839A JP 2023509839 A JP2023509839 A JP 2023509839A JP 2023538326 A JP2023538326 A JP 2023538326A
Authority
JP
Japan
Prior art keywords
compound
alkyl
aryl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538326A5 (https=
Inventor
ジェイ． テペ、ジェッツェ
ヴァネチェク、アリソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University MSU
Original Assignee
Michigan State University MSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University MSU filed Critical Michigan State University MSU
Publication of JP2023538326A publication Critical patent/JP2023538326A/ja
Publication of JP2023538326A5 publication Critical patent/JP2023538326A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023509839A 2020-08-11 2021-08-10 プロテアソームエンハンサ及びその使用 Pending JP2023538326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064262P 2020-08-11 2020-08-11
US63/064,262 2020-08-11
PCT/US2021/045440 WO2022035898A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof

Publications (2)

Publication Number Publication Date
JP2023538326A true JP2023538326A (ja) 2023-09-07
JP2023538326A5 JP2023538326A5 (https=) 2024-08-19

Family

ID=83103398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509839A Pending JP2023538326A (ja) 2020-08-11 2021-08-10 プロテアソームエンハンサ及びその使用

Country Status (7)

Country Link
US (1) US20230295116A1 (https=)
EP (1) EP4196119A4 (https=)
JP (1) JP2023538326A (https=)
AU (1) AU2021324684A1 (https=)
CA (1) CA3191437A1 (https=)
MX (1) MX2023001758A (https=)
WO (1) WO2022035898A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054147A1 (en) * 2023-09-07 2025-03-13 Cfd Research Corporation Ph-responsive astemizole nanoparticles and methods for making and using the same
CN120118039B (zh) * 2023-12-07 2025-11-28 南华大学 含芳基脲结构的苯并咪唑类衍生物、制造方法及其用途
WO2025219559A1 (en) * 2024-04-18 2025-10-23 Booster Therapeutics Gmbh Pyrrolidine compounds as proteasome stimulators

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
JP2010520876A (ja) * 2007-03-09 2010-06-17 アストラゼネカ・アクチエボラーグ ピペラジンおよびピペリジンｍＧｌｕＲ５増強剤
JP2010533725A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物
WO2014027053A1 (en) * 2012-08-14 2014-02-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Benzimidazoles for the treatment of cancer
JP2014509317A (ja) * 2011-02-09 2014-04-17 プサン ナショナル ユニヴァーシティ インダストリー ユニヴァーシティ 皮膚美白、抗酸化及びｐｐａｒ活性を有する新規化合物及びその医学的用途
CN107556318A (zh) * 2017-08-22 2018-01-09 山东大学 一种含哌啶的吡咯并嘧啶类化合物及其制备方法与应用
KR101893879B1 (ko) * 2017-03-31 2018-09-03 한국화학연구원 신규한 cdk 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 cdk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2019084157A1 (en) * 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2019156991A1 (en) * 2018-02-06 2019-08-15 The Regents Of The University Of California Methods of inhibiting formation of alpha synuclein aggregates
WO2020041100A1 (en) * 2018-08-22 2020-02-27 Merck Sharp & Dohme Corp. Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
ES555340A0 (es) * 1985-06-18 1986-11-16 Euroargenmex S A Un nuevo procedimiento de preparacion de 2-(4-piperidilamino) benimidazoles
US5314903A (en) * 1991-12-03 1994-05-24 Neurosearch A/S Benzimidazole compounds useful as calcium channel blockers
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2008084218A1 (en) * 2007-01-12 2008-07-17 Boehringer Ingelheim International Gmbh Benzazole derivatives for the treatment of inflammations
WO2010010187A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JP5782234B2 (ja) * 2010-06-16 2015-09-24 チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ ベンゾイミダゾール化合物およびその使用
WO2012020567A1 (en) * 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
CA2829558A1 (en) * 2011-03-09 2012-09-13 Celgene Avilomics Research, Inc. Pi3 kinase inhibitors and uses thereof
CN103044337A (zh) * 2011-10-13 2013-04-17 南京理工大学 2-(n-烷基)氨基咪唑衍生物的合成方法
AU2013216354B2 (en) * 2012-02-02 2017-08-31 Idorsia Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
HUE039922T2 (hu) * 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
CN110845423A (zh) * 2019-12-06 2020-02-28 井冈山大学 一种1,2-取代苯并咪唑类化合物的制备方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
JP2010520876A (ja) * 2007-03-09 2010-06-17 アストラゼネカ・アクチエボラーグ ピペラジンおよびピペリジンｍＧｌｕＲ５増強剤
JP2010533725A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物
JP2014509317A (ja) * 2011-02-09 2014-04-17 プサン ナショナル ユニヴァーシティ インダストリー ユニヴァーシティ 皮膚美白、抗酸化及びｐｐａｒ活性を有する新規化合物及びその医学的用途
WO2014027053A1 (en) * 2012-08-14 2014-02-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Benzimidazoles for the treatment of cancer
KR101893879B1 (ko) * 2017-03-31 2018-09-03 한국화학연구원 신규한 cdk 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 cdk 관련 질환의 예방 또는 치료용 약학적 조성물
CN107556318A (zh) * 2017-08-22 2018-01-09 山东大学 一种含哌啶的吡咯并嘧啶类化合物及其制备方法与应用
WO2019084157A1 (en) * 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2019156991A1 (en) * 2018-02-06 2019-08-15 The Regents Of The University Of California Methods of inhibiting formation of alpha synuclein aggregates
WO2020041100A1 (en) * 2018-08-22 2020-02-27 Merck Sharp & Dohme Corp. Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Also Published As

Publication number Publication date
AU2021324684A1 (en) 2023-04-20
EP4196119A4 (en) 2024-07-31
US20230295116A1 (en) 2023-09-21
EP4196119A1 (en) 2023-06-21
WO2022035898A1 (en) 2022-02-17
CA3191437A1 (en) 2022-02-17
MX2023001758A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
CN102264707B (zh) 双环型杂环化合物
JP2023538326A (ja) プロテアソームエンハンサ及びその使用
KR102212981B1 (ko) 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약
TW200530195A (en) Benzimidazole derivatives: preparation and pharmaceutical applications
JP7178375B2 (ja) デュアルｍａｇｌ及びｆａａｈインヒビター
EA024391B1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
KR20240144965A (ko) 단백질 티로신 포스파타제의 억제제, 조성물 및 사용 방법
US11964960B2 (en) Pyridinone- and pyridazinone-based compounds and uses thereof
CA2824536A1 (en) Protease activated receptor 2 (par2) antagonists
JPWO2005030773A1 (ja) 新規ピラゾロピリミジン誘導体
JP5667934B2 (ja) 新規２環性複素環化合物からなる医薬
ES2664418T3 (es) Compuestos de fluorofenil pirazol
CA3012812A1 (en) Heterocyclic sulfonamide derivative and medicine containing same
KR102472103B1 (ko) 국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체
US20250179031A1 (en) Proteasome enhancers and uses thereof
US20140242099A1 (en) Compounds for inflammation and immune-related uses
US20130289071A1 (en) Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
JP2023537994A (ja) プロテアソームエンハンサーおよびその使用
JP2023538325A (ja) プロテアソームエンハンサー及びその使用
WO2024206093A1 (en) Hiv-1p rotease inhibitors and uses thereof
HK1162504B (en) Novel bicyclic heterocyclic compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240808

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217